Table 1 Patient and tumor characteristics for the 200 HER2+ tumors and the 554 HER2- reference breast cancer data set
| Â | HER2+ | HER2-* |
|---|---|---|
Number of tumors | 200 | 554 |
Number of primary tumors | 176 | -- |
Number of metastases | 5 | -- |
Unknown status | 19 | -- |
Tumor size | Â | Â |
≤20 mm | 57 | 205 |
>20 mm | 134 | 226 |
Mean size mm (SD) | 29 (16) | 26 (14) |
Histological grade | Â | Â |
Grade 1 | 1 | 41 |
Grade 2 | 26 | 134 |
Grade 3 | 38 | 134 |
Estrogen receptor status | Â | Â |
Positive | 76 | 306 |
Negative | 122 | 149 |
Lymph node status | Â | Â |
Negative | 69 | 244 |
Positive | 123 | 194 |
Age | Â | Â |
Median age in years (range) | 56 (27 to 84) | 55 (28 to 94) |
<50 years | 77 | 212 |
≥50 years | 109 | 252 |
DNA ploidy status | Â | Â |
Aneuploid | 112 | -- |
Diploid | 39 | -- |
Unknown | 49 | -- |
Gene expression subtype** | Â | Â |
Basal-like | 7 | 135 |
ERBB2 | 51 | 6 |
Normal-like | 9 | 35 |
Luminal A | 4 | 153 |
Luminal B | 10 | 77 |
Unclassified | 6 | 42 |
Overall survival*** | Â | Â |
Number of deaths | 109 | 190 |
Within five years | 80 | 107 |
Median survival in years (range) | 7 (0.16 to 18.5) | 7.6 (0.1 to 31.9) |
Median follow-up in years for patients still alive (range) | 12.8 (7 to 18.5) | 10.2 (1.5 to 20.2) |